Jump Financial’s Cytek Biosciences CTKB Stock Holding History

Jump Financial’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$126K	Buy	+28,892	New	+$136K	﹤0.01%	1729
2024 Q4	–	Sell	-73,697	Closed	-$408K	–	1715
2024 Q3	$408K	Buy	+73,697	New	+$418K	0.01%	1185
2023 Q4	–	Sell	-43,404	Closed	-$240K	–	1863
2023 Q3	$240K	Buy	+43,404	New	+$348K	0.01%	1423
2023 Q2	–	Sell	-99,089	Closed	-$911K	–	1861
2023 Q1	$911K	Buy	99,089 +26,479	+36%	+$285K	0.04%	635
2022 Q4	$741K	Buy	+72,610	New	+$976K	0.04%	614
2022 Q2	–	Sell	-34,854	Closed	-$376K	–	1686
2022 Q1	$376K	Buy	+34,854	New	+$471K	0.02%	950

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jump Financial's CTKB Position: Q1 2026 in Review

Jump Financial opened a new position in Cytek Biosciences (CTKB) in Q1 2026: 28,892 shares worth $126K. The stake represents ﹤0.01% of the portfolio and ranks #1729 among its holdings. This is a return to the name: Jump Financial previously reported a position in CTKB as recently as Q3 2024.

Jump Financial first reported a position in CTKB in Q1 2022 and has held it in 6 quarters since. The position peaked at $911K in Q1 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

Jump Financial held 28,892 shares of Cytek Biosciences worth $126K as of Q1 2026.
Cytek Biosciences was a new Jump Financial position in Q1 2026.
Cytek Biosciences made up ﹤0.01% of Jump Financial's portfolio in Q1 2026, its #1729 holding.
Jump Financial first reported a position in Cytek Biosciences in Q1 2022 and has held it in 6 quarters since.
Jump Financial's Cytek Biosciences position peaked at $911K in Q1 2023.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.